论文信息 - Abstract 17: Preclinical and phase 1 trial results of JI-101, a novel, oral tyrosine kinase inhibitor that selectively targets VEGFR2, EphB4, and PDGFRβ - 字舞流文

Abstract 17: Preclinical and phase 1 trial results of JI-101, a novel, oral tyrosine kinase inhibitor that selectively targets VEGFR2, EphB4, and PDGFRβ

D. Brittelli | L. Miller | M. Velleca | M. Gordon | D. Qian | Sreesha P. Srinivasa | S. Mitchell | L. Elkin | R. Govindarajan | Xiaobing Qian | W. Stern | Udo Klein | Sunil Sharma | T. Stephen | N. Nandhagopal